Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Obstetrics and Gynecology (Majalah Obstetri dan Ginekologi Indonesia) Cermin Dunia Kedokteran
Biran Affandi
POGI/Department of Obstetrics and Gynecology, Faculty of Medicine Universitas Indonesia, Jakarta.
Health Professions Medicine & Pharmacology Public Health

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 7 Documents
Search

 1 
Postplacental IUCD CuT380A: Acceptability, Effectivity and Side Effects Situmorang, Herbert; Setijanto, Ivanna T; Affandi, Biran
Indonesian Journal of Obstetrics and Gynecology Volume. 5, No. 4, October 2017
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (105.123 KB) | DOI: 10.32771/inajog.v5i4.563

Abstract

Objective: To evaluate the acceptability, effectivity and side effects of Postplacental IUCD after vaginal delivery at Dr. Cipto Mangunkusumo Hospital (RSCM) after 6 month of insertion. Methods: A prospective study was conducted at RSCM Jakarta during the period of August to October 2012. Postplacental IUCD was inserted into the subjects’ uterus until it reached the fundus. Follow up was done at 40-42 days and 6 months after delivery.  Results: A total of 234 women were recruited in this study, with 19.2% loss of follow up. No significant difference on subjects characteristics who came and loss of follow up in this study. Expulsion was experienced by 5.1% subjects (total expulsion 4.1% and partial 1%) at the first visit on 40-42 days and 7.5% subjects (total expulsion 0.6% and partial 6.9%) at the second visit, after 6 months. 9.3% subjects had the IUCD removed at the first and second visit. Among all of the subjects who had the IUCD removed by request or had the expulsion, 61% were willing to do reinsertion. The effectivity of IUCD was 100%, with 68.9% subjects was still breastfeeding. The side effects were vaginal discharge (23%), dysmenorrhea (4-21%), and spotting (2-10%).  Conclusion: The acceptability and effectivity of postplacental IUCD after 6 months were 86.8% and 100%. Cummulative expulsion rate were 12.6%, and the most common side effects were vaginal discharge, dysmenorea, and spotting. Keywords: acceptability, effectivity, expulsion rate, IUD, postplacenta
A Randomized FiveYear Comparative Study of Two LevonorgestrelReleasing Implant Systems: Norplant® Capsules and Jadena® Rods Affandi, Biran; Ridwan, Rusdi S; Hoesni, R Hasan M; Tandjung, Thamrin; Ichsan, TM; Amran, Rizani; Manan, Heriyadi; Gunardi, Eka R; Pramana, Noor; Hadiyono, Suryo; Widohariadi, Widohariadi; Farid, Retno B; Taher, Mardiah
Indonesian Journal of Obstetrics and Gynecology Volume 4, No. 4, October 2016
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (120.478 KB) | DOI: 10.32771/inajog.v4i4.447

Abstract

Objective: To provide a randomized comparison between Jadena® and Norplant® in terms of efficacy and acceptability among Indonesian women. Method: This study was a phase IV, open label, randomized, multicenter study throughout Indonesia. Subjects were Indonesian adult women who were randomized to receive Jadena® or Norplant® as their contraceptive method. The subjects were recruited from 6 large cities in Indonesia, such as Medan, Palembang, Jakarta, Semarang, Surabaya, and Makassar. Result: Of 600 subjects, 301 women getting to Jadena® and 299 women to Norplant® were enrolled between August 1998 and February 1999. The mean age was 29.8 (SD 5.3) years old, ranging from 18 to 40 years old. We did not find the pregnancy during the study. Non-pregnancy probability at the end of one year was similar between Jadena® (0.920 (SD 0.016)) and Norplant® users (0.916 (SD 0.084)). The continuation rates of Jadena® at one and three-year were 95.3% and 66.8%; whereas, the continuation rates of Norplant® was 94.3% at year-1 and 70.2% at year-3. Conclusion: The new two rod levonorgestrel subdermal system (Jadena®) showed similar efficacy with the old six capsule levonorgestrel subdermal system (Norplant®) in term of birth control. Both implant systems also have similar tolerability profile. Jadena® is easier to insert and remove than Norplant®. Keywords: birth control, efficacy, implant
Gynecology Cancer in Relationship with Obesity Rauw, Gracia M R G; Laihad, Bismarck J; Affandi, Biran
Indonesian Journal of Obstetrics and Gynecology Volume. 4, No. 1, January 2016
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (67.324 KB) | DOI: 10.32771/inajog.v4i1.68

Abstract

Objective: To know the relationship between obesity and gynecology cancer. Method: This study use case control study design for 250 gynecology patients (125 controls and 125 cases) in Prof. Dr. R. D. Kandou Manado Hospital from 1 July to 30 November 2015. The data was collected by measuring Body Mass Index (BMI) and filing out selfadministered questioners. Result: From the 250 subjects, the study group (125 subjects), 72 subjects have obesity (57.6%) and 97 subjects have multiple parities (77.6%) with 58 subjects diagnosed with cervical cancer (46.4%). In the control group (125 subjects), 71 subjects have normal weight (56.8%) and 67 subjects have multiple parities (53.6%) with 64 subjects diagnosed with ovarium cysts (51.2%). Using multivariate logistic regression, the overweight and obese subjects have 7 folds higher risk to develop gynecology cancer compared to those with normal or underweight subjects. Those with multiple parities and grande multipara subjects have 3 folds higher risk to develop gynecology cancer compared with those who are nullipara and primipara. Conclusion: A significant correlation is found between obesity and gynecology cancer using multivariate logistic regression analysis (p=0.000, OR=6.9 (95% CI = 3.62-13.13). [Indones J Obstet Gynecol 2016; 1: 23-30] Keywords: gynecology cancer, multiple parities, obesity
Gynecology Cancer in Relationship with Obesity Rauw, Gracia M R G; Laihad, Bismarck J; Affandi, Biran
Indonesian Journal of Obstetrics and Gynecology Volume. 4, No. 1, January 2016
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (67.324 KB) | DOI: 10.32771/inajog.v4i1.68

Abstract

Objective: To know the relationship between obesity and gynecology cancer. Method: This study use case control study design for 250 gynecology patients (125 controls and 125 cases) in Prof. Dr. R. D. Kandou Manado Hospital from 1 July to 30 November 2015. The data was collected by measuring Body Mass Index (BMI) and filing out selfadministered questioners. Result: From the 250 subjects, the study group (125 subjects), 72 subjects have obesity (57.6%) and 97 subjects have multiple parities (77.6%) with 58 subjects diagnosed with cervical cancer (46.4%). In the control group (125 subjects), 71 subjects have normal weight (56.8%) and 67 subjects have multiple parities (53.6%) with 64 subjects diagnosed with ovarium cysts (51.2%). Using multivariate logistic regression, the overweight and obese subjects have 7 folds higher risk to develop gynecology cancer compared to those with normal or underweight subjects. Those with multiple parities and grande multipara subjects have 3 folds higher risk to develop gynecology cancer compared with those who are nullipara and primipara. Conclusion: A significant correlation is found between obesity and gynecology cancer using multivariate logistic regression analysis (p=0.000, OR=6.9 (95% CI = 3.62-13.13). [Indones J Obstet Gynecol 2016; 1: 23-30] Keywords: gynecology cancer, multiple parities, obesity
A Randomized FiveYear Comparative Study of Two LevonorgestrelReleasing Implant Systems: Norplant® Capsules and Jadena® Rods Affandi, Biran; Ridwan, Rusdi S; Hoesni, R Hasan M; Tandjung, Thamrin; Ichsan, TM; Amran, Rizani; Manan, Heriyadi; Gunardi, Eka R; Pramana, Noor; Hadiyono, Suryo; Widohariadi, Widohariadi; Farid, Retno B; Taher, Mardiah
Indonesian Journal of Obstetrics and Gynecology Volume 4, No. 4, October 2016
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (120.478 KB) | DOI: 10.32771/inajog.v4i4.447

Abstract

Objective: To provide a randomized comparison between Jadena® and Norplant® in terms of efficacy and acceptability among Indonesian women. Method: This study was a phase IV, open label, randomized, multicenter study throughout Indonesia. Subjects were Indonesian adult women who were randomized to receive Jadena® or Norplant® as their contraceptive method. The subjects were recruited from 6 large cities in Indonesia, such as Medan, Palembang, Jakarta, Semarang, Surabaya, and Makassar. Result: Of 600 subjects, 301 women getting to Jadena® and 299 women to Norplant® were enrolled between August 1998 and February 1999. The mean age was 29.8 (SD 5.3) years old, ranging from 18 to 40 years old. We did not find the pregnancy during the study. Non-pregnancy probability at the end of one year was similar between Jadena® (0.920 (SD 0.016)) and Norplant® users (0.916 (SD 0.084)). The continuation rates of Jadena® at one and three-year were 95.3% and 66.8%; whereas, the continuation rates of Norplant® was 94.3% at year-1 and 70.2% at year-3. Conclusion: The new two rod levonorgestrel subdermal system (Jadena®) showed similar efficacy with the old six capsule levonorgestrel subdermal system (Norplant®) in term of birth control. Both implant systems also have similar tolerability profile. Jadena® is easier to insert and remove than Norplant®. Keywords: birth control, efficacy, implant
Postplacental IUCD CuT380A: Acceptability, Effectivity and Side Effects Situmorang, Herbert; Setijanto, Ivanna T; Affandi, Biran
Indonesian Journal of Obstetrics and Gynecology Volume. 5, No. 4, October 2017
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (105.123 KB) | DOI: 10.32771/inajog.v5i4.563

Abstract

Objective: To evaluate the acceptability, effectivity and side effects of Postplacental IUCD after vaginal delivery at Dr. Cipto Mangunkusumo Hospital (RSCM) after 6 month of insertion. Methods: A prospective study was conducted at RSCM Jakarta during the period of August to October 2012. Postplacental IUCD was inserted into the subjects’ uterus until it reached the fundus. Follow up was done at 40-42 days and 6 months after delivery.  Results: A total of 234 women were recruited in this study, with 19.2% loss of follow up. No significant difference on subjects characteristics who came and loss of follow up in this study. Expulsion was experienced by 5.1% subjects (total expulsion 4.1% and partial 1%) at the first visit on 40-42 days and 7.5% subjects (total expulsion 0.6% and partial 6.9%) at the second visit, after 6 months. 9.3% subjects had the IUCD removed at the first and second visit. Among all of the subjects who had the IUCD removed by request or had the expulsion, 61% were willing to do reinsertion. The effectivity of IUCD was 100%, with 68.9% subjects was still breastfeeding. The side effects were vaginal discharge (23%), dysmenorrhea (4-21%), and spotting (2-10%).  Conclusion: The acceptability and effectivity of postplacental IUCD after 6 months were 86.8% and 100%. Cummulative expulsion rate were 12.6%, and the most common side effects were vaginal discharge, dysmenorea, and spotting. Keywords: acceptability, effectivity, expulsion rate, IUD, postplacenta
The Efficacy and Safety of Two Depo Medroxyprogesterone Acetate Injection Preparations as Contraception: An Open-Label, Randomized Controlled Study Rosdiana, Dewi Selvina; K. Suherman, Suharti; Affandi, Biran; Gunadi, E. Rusdianto; Amelia, Dwirani; Baharrudin, Mohammad
Cermin Dunia Kedokteran Vol 44, No 5 (2017): Gastrointestinal
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (250.93 KB) | DOI: 10.55175/cdk.v44i5.794

Abstract

Latar belakang: Kontrasepsi hormonal injeksi masih banyak digunakan di berbagai negara berkembang, termasuk di Indonesia. Tujuan penelitian ini adalah untuk membandingkan efikasi dan keamanan kontrasepsi hormonal injeksi mengandung 150 mg/mL medroxyprogesterone acetate (DMPA) (obat A) yang akan digunakan untuk program Keluarga Berencana Nasional, dibandingkan dengan inovatornya (obat B). Metode: penelitian ini open-label, acak, multisenter, 2 kelompok, melibatkan 400 subjek usia produktif, yang diacak untuk mendapatkan obat A atau obat B. Injeksi diberikan sekali setiap 3 bulan, selama 1 tahun. Hasil: Setelah 4 kali injeksi kontrasepsi periode satu tahun, tidak didapatkan kehamilan pada kedua kelompok, nilai Pearl-Index masing-masing kelompok nol. Insidensi kejadian tidak diinginkan sebanding pada kedua kelompok dan dapat ditoleransi, dengan kejadian paling sering adalah amenore, spotting, sakit kepala dan menstruasi memanjang. Simpulan: Kontrasepsi hormonal injeksi yang akan digunakan untuk program KB nasional (obat A) memiliki efikasi dan keamanan yang sebanding dengan inovatornya (obat B).Backgroud: Injectable hormonal contraceptives remain in extensive use in many developing countries, including Indonesia. This study was intended to compare the efficacy and safety of injectable hormonal contraception contain 150 mg/mL DMPA injection (Drug A), that will be used for national Family Planning Program, versus the innovator product (Drug B). Methods: This study was an open-label, randomized, multicenter, 2-parallel group study, involving 400 women of childbearing age, who received Drug A or Drug B four times at 3-month intervals. Results: No pregnancies occur in both groups after 4 injections of Drug A or Drug B over a period of 12 months, the Pearl-Index value for each group was zero. The incidence of adverse events between groups were comparable and tolerable, the most common events were amenorrhea, spotting, headache, and prolonged menstruation. Conclusion: The efficacy and safety of injectable DMPA (Drug A) produced for National Family Planning program was comparable with the innovator DMPA drug (Drug B).
Co-Authors Abdul B. Saifuddin Agus Sopacua Aldri Frinaldi Amelia, Dwirani Baharrudin, Mohammad Bimo Bimo Bismarck J Laihad Budiningsih Siregar Clayton Ajello Djajadilaga Djajadilaga Eka R Gunardi Eka R. Gunardi Farid, Retno B Fitriani Iskandar Gunadi, E. Rusdianto H.J.T Coelingh Bennink H.J.T. Coelingh Bennink H.M. Hoesni Hadiyono, Suryo Herbert Situmorang Herbert Situmorang Hoesni, R Hasan M Ichsan, TM K. Suherman, Suharti Lila Dewata Manan, Heriyadi Manan, Heriyadi N.P. Noerpramono Peter A.W. Rogers Pramana, Noor R.P. Barus Rauw, Gracia M R G Ridwan, Rusdi S Rizani Amran Rosdiana, Dewi Selvina Setijanto, Ivanna T Sugito Wonodirekso Suharti K. Suherman T.B. Paul Geurts Taher, Mardiah Tandjung, Thamrin Tjeerd Korver W. Gadroen W. Ngartjono Wachju Hadisaputra Wachyu Hadisaputra Widohariadi Widohariadi